First fractures among postmenopausal women with osteoporosis
- 7 January 2010
- journal article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 28 (4) , 485-488
Abstract
After the occurrence of the first fracture, osteoporosis is no longer a “silent” disease, and the patient’s risk for future fracture is increased several fold. We assessed the location of first osteoporotic fractures among women with osteoporosis. The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was a fracture outcomes study of postmenopausal women with osteoporosis. All subjects received supplements containing 500 mg elemental calcium and 400–600 IU vitamin D. We assessed the location of first fractures among women with osteoporosis and no previous fractures at baseline from the placebo group of this trial after 3 years of follow-up. Prespecified fracture sites included vertebral fractures and nonvertebral fractures as defined in the MORE study protocol. Among 875 women (mean age, 64.5 ± 7.4 years) with no prevalent vertebral or nonvertebral fractures, 9% experienced their first fracture event during the trial. Fractures of radius and spine each occurred in 3% of patients. Fractures at other individual sites included ankle (0.6%), metatarsal (0.6%), humerus (0.5%), rib (0.5%), patella (0.3%), leg (0.2%), hip (0.2%), and clavicle (0.1%). These data suggest that for postmenopausal women with osteoporosis but no previous fractures, skeletal care should include a focus on preventing spine and radius fractures.Keywords
This publication has 12 references indexed in Scilit:
- National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone TechnologistJournal of Clinical Densitometry, 2008
- Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025Journal of Bone and Mineral Research, 2007
- Enhanced prediction of fracture risk combining vertebral fracture status and BMDOsteoporosis International, 2007
- Comparison of Fracture, Cardiovascular Event, and Breast Cancer Rates at 3 Years in Postmenopausal Women with OsteoporosisJournal of the American Geriatrics Society, 2004
- Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial11Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.Bone, 2003
- Distal Radius Fractures in Older Women: A 10‐Year Follow‐Up Study of Descriptive Characteristics and Risk Factors. The Study of Osteoporotic FracturesJournal of the American Geriatrics Society, 2002
- Risk of New Vertebral Fracture in the Year Following a FractureJAMA, 2001
- Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal siteAging Clinical and Experimental Research, 2000
- Vertebral Fractures Predict Subsequent FracturesOsteoporosis International, 1999
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999